Clinical Scorecard: The Contradiction of Antibiotic Use in Allogeneic Stem Cell Transplantation
At a Glance
Category
Detail
Condition
Infections and acute gastrointestinal Graft-versus-Host Disease (GvHD) in allogeneic stem cell transplantation
Key Mechanisms
Antibiotics treat infections but cause intestinal dysbiosis leading to increased GvHD risk; antibiotics also suppress bacterial translocation that triggers GvHD
Target Population
Patients undergoing allogeneic stem cell transplantation (ASCT) with neutropenia and immunodeficiency
Bloodstream infections occur in 13-30% of ASCT recipients, increasing mortality and requiring immediate empiric broad-spectrum antibiotics.
Early and prolonged antibiotic use causes intestinal dysbiosis, loss of protective bacteria, and increased risk of severe acute GI GvHD.
Antibiotic paradox: antibiotics can both enhance GvHD risk via dysbiosis and suppress GvHD by eliminating translocated bacteria that activate T cells.
Guideline-Based Recommendations
Diagnosis
Immediate diagnosis of infections during neutropenia is critical; microbial cultures guide adapted antibiotic treatment.
Distinguish fever of unknown origin (FUO) from cytokine release syndrome (CRS) to avoid unnecessary early antibiotic use.
Management
Start broad-spectrum antibiotics at onset of febrile neutropenia or FUO.
De-escalate and discontinue antibiotics during neutropenia once infections clear, per current guidelines.
Implement restrictive antibiotic protocols to reduce early antibiotic exposure, especially in patients at risk of CRS.
Monitoring & Follow-up
Monitor microbiota diversity and signs of dysbiosis to assess risk of acute GI GvHD.
Use emerging molecular techniques to detect microbiota changes and improve infection diagnostics.
Risks
Prolonged antibiotic use leads to intestinal dysbiosis, loss of short chain fatty acids and indoles, increasing epithelial damage and GvHD susceptibility.
Broad-spectrum antibiotics with extensive anaerobic coverage may impair CAR T-cell therapy efficacy by disrupting microbiome diversity.
Patient & Prescribing Data
ASCT recipients and patients receiving CAR T-cell therapy
Early and prolonged broad-spectrum antibiotics increase dysbiosis and GvHD risk; however, short antibiotic courses post-CAR T infusion (<10 days) do not compromise treatment efficacy.
Clinical Best Practices
Adhere to antibiotic stewardship with prompt de-escalation and discontinuation once infections resolve.
Restrict early antibiotic use in patients likely to develop fever due to CRS to reduce unnecessary exposure.
Consider microbiota-preserving strategies and emerging diagnostics to balance infection control and microbiome health.
Recognize the dual role of antibiotics in modulating T-cell mediated immunity and tailor therapy accordingly.
by Daniela Weber, Elisabeth Meedt, Sakhila Ghimire, Andreas Hiergeist, Michael A. G. Kern, Matthias Höpting, Erik Thiele Orberg, Haroon Shaikh, Andreas Beilhack, Daniel Wolff, Matthias Edinger, Wolfgang Herr, Andre Gessner, Hendrik Poeck, Ernst Holler
